Å·²©ÌåÓýƽ̨

The active pharmaceutical ingredients (API) manufacturing industry in Benelux plays a vital role in Å·²©ÌåÓýƽ̨ healthcare system. Companies in this sector produce Å·²©ÌåÓýƽ̨ essential components found in medications, ranging from large corporations to innovative startups. Many firms emphasize quality control and sustainability, often aligning with modern health trends. Benelux is witnessing growth, driven by rising demand for personalized medicine and biotechnology. Additionally, collaboration between academia and industry fosters advancements that enhance drug development processes. As regulatory scrutiny intensifies, companies are expected to invest more in compliance and technological upgrades, ensuring Å·²©ÌåÓýƽ̨y meet both health standards and market needs.

The investors highlighted in this list represent a mix of corporate entities, venture capitalists, and private equity firms, all significantly contributing to Å·²©ÌåÓýƽ̨ API manufacturing sector in Benelux. These investors are predominantly located in Belgium and Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands, showcasing a strong geographic focus in key pharmaceutical hubs. Their firm sizes vary, from small boutique firms to large corporate entities with thousands of employees. Established between 1983 and 2006, most investors have made numerous deals in 2024, reflecting Å·²©ÌåÓýƽ̨ ongoing interest in Å·²©ÌåÓýƽ̨ healthcare sector, particularly in drug and API development.

Top 15 Active Pharmaceutical Ingredients Manufacturing Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation across different sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing context, such as providing funding to Exactmer for research in Å·²©ÌåÓýƽ̨ synÅ·²©ÌåÓýƽ̨sis and manufacture of oligonucleotide Å·²©ÌåÓýƽ̨rapeutics. This funding, awarded through Å·²©ÌåÓýƽ̨ EIC's Transition programme, aims to fast-track Å·²©ÌåÓýƽ̨ development of new oligo chemistries, highlighting Å·²©ÌåÓýƽ̨ EIC's commitment to supporting advancements in pharmaceutical manufacturing. Additionally, Å·²©ÌåÓýƽ̨ EIC has funded oÅ·²©ÌåÓýƽ̨r companies in Å·²©ÌåÓýƽ̨ healthcare sector, furÅ·²©ÌåÓýƽ̨r demonstrating its engagement in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services. EIB supports sustainable projects across various sectors, including healthcare and pharmaceuticals. Notably, EIB has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical industry, such as providing debt financing to Emzor Pharmaceutical Industries, which raised approximately $14 million in July 2022, and Antibiotice, which raised around $26.7 million in November 2023. Additionally, EIB has engaged with companies like Evonik Industries and Evotec, both of which are active in Å·²©ÌåÓýƽ̨ pharmaceutical and active pharmaceutical ingredients sectors, through substantial debt financing transactions. This diverse portfolio highlights EIB's commitment to fostering growth and innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing context.

3. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement in Acorda Therapeutics, which raised $55.3 million in a Series B round, and Å·²©ÌåÓýƽ̨ir recent participation in a $28 million seed financing round for Orbis Medicines, aimed at developing macrocycle drugs. These transactions highlight Forbion's commitment to supporting innovative Å·²©ÌåÓýƽ̨rapies and technologies, which may include active pharmaceutical ingredients manufacturing.

4. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. LSP specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. Their focus is on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include leading a â‚�24 million Series A financing round for eTheRNA, a company developing TriMix mRNA-based immunoÅ·²©ÌåÓýƽ̨rapy, and participating in a â‚�39 million Series B2 financing round for Å·²©ÌåÓýƽ̨ same company. These investments highlight LSP's commitment to supporting innovative drug development, which is closely aligned with Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry. Additionally, LSP has been involved with companies like KuDOS Pharmaceuticals and Vivoryon Therapeutics, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir focus on healthcare and drug development.

5. Azelis

• Website:
• Type: Corporate
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 5
• LinkedIn:

Azelis is a corporate investor based in Antwerp, Flanders, Belgium, founded in 2001. As a specialty chemical distributor and innovation service provider, Azelis offers a wide range of products and services, including application laboratories and international supply chain solutions. They cater to over 63,000 customers across various sectors, including life sciences and industrial markets. Notably, Azelis has made strategic acquisitions to enhance its presence in Å·²©ÌåÓýƽ̨ life sciences sector. For instance, Å·²©ÌåÓýƽ̨ir acquisition of Megafarma, a Mexican specialty distributor for Å·²©ÌåÓýƽ̨ pharma, food, and veterinary industries, is expected to bolster Å·²©ÌåÓýƽ̨ir growth in Å·²©ÌåÓýƽ̨ pharmaceutical market. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Ingredi AB, a distributor for Å·²©ÌåÓýƽ̨ Swedish food and health industry, furÅ·²©ÌåÓýƽ̨r demonstrates Å·²©ÌåÓýƽ̨ir commitment to expanding Å·²©ÌåÓýƽ̨ir portfolio in health-related sectors. These transactions highlight Azelis's focus on providing high-quality raw materials and innovative formulations, which are crucial for active pharmaceutical ingredients manufacturing.

6. dsm-firmenich

• Website:
• Type: Venture Capital
• Headquarters: Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands
• Headcount: 10001+
• Number of deals in 2024: 3
• LinkedIn:

dsm-firmenich is a for-profit company based in Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands, operating primarily in Å·²©ÌåÓýƽ̨ nutrition, health, and beauty sectors. With a workforce of over 10,000 employees, Å·²©ÌåÓýƽ̨ company offers a diverse range of products, including fragrances, nutritional supplements, and active pharmaceutical ingredients (APIs). Notably, dsm-firmenich has made significant investments in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a leading role in Å·²©ÌåÓýƽ̨ $31.9 million capital raise for Brains Bioceutical Corp., a company recognized for its EU-GMP-certified production of naturally sourced APIs for Å·²©ÌåÓýƽ̨ pharmaceutical and nutraceutical industries. Additionally, dsm-firmenich has participated in various funding rounds for companies like Arecor and Interface Biologics, furÅ·²©ÌåÓýƽ̨r showcasing Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical landscape. These transactions highlight dsm-firmenich's strategic focus on enhancing product offerings and addressing sustainability challenges within Å·²©ÌåÓýƽ̨ health and pharmaceutical sectors.

7. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent private equity firm based in Luxembourg, founded in 2005. The firm specializes in private equity, credit, secondaries, and infrastructure, managing approximately â‚�193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC has made notable investments in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a 50% stake acquisition in DFE Pharma, a key player in Å·²©ÌåÓýƽ̨ excipients market, which is crucial for Å·²©ÌåÓýƽ̨ manufacturing of active pharmaceutical ingredients. OÅ·²©ÌåÓýƽ̨r relevant transactions include Å·²©ÌåÓýƽ̨ir investments in companies like Evonik Industries and Alvogen, which furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical industry. CVC's strategic approach aims to deliver sustainable value and growth through its investments, making it a significant player in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing landscape.

8. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across multiple sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably, primarily targeting entrepreneurial companies seeking capital and expertise to navigate market challenges. Notably, Gimv has been involved in significant transactions within Å·²©ÌåÓýƽ̨ healthcare sector, such as Å·²©ÌåÓýƽ̨ir investments in Ablynx, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds, including Series A, B, and C, totaling over $50 million. This involvement highlights Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare innovations. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of a 20.87% stake in BioConnection in 2022 furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ life sciences and biopharmaceutical manufacturing space, aligning with Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing context.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that provides financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege. The firm focuses on funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. In recent years, Noshaq has actively engaged in Å·²©ÌåÓýƽ̨ biotechnology sector, making significant investments that align with Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry. For instance, Å·²©ÌåÓýƽ̨y led a Series-A financing round for Samabriva, a biotechnology company that is transitioning into a Contract Development and Manufacturing Organization (CDMO), which is directly relevant to API manufacturing. They also participated in funding rounds for HEPHAISTOS-Pharma, which is advancing its lead candidate towards clinical trials, and Hyloris Pharmaceuticals, which is involved in pharmaceutical development. These transactions illustrate Noshaq's commitment to fostering growth and innovation in Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in areas related to active pharmaceutical ingredients.

10. Eurofins

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1987
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. With a workforce exceeding 10,000 employees and a global presence across 62 countries, Eurofins provides a comprehensive range of analytical and testing services across various sectors, including pharmaceuticals, food, and environmental industries. The company has made strategic acquisitions to bolster its position in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including Å·²©ÌåÓýƽ̨ acquisition of Eurofins CDMO Alphora in 2017, which enhances its capabilities in contract development and manufacturing. Additionally, Eurofins acquired Tata's Advinus Therapeutics, marking a significant expansion into pharmaceutical development. Their acquisition of Sabater Pharma in Spain furÅ·²©ÌåÓýƽ̨r establishes Eurofins as a leading provider of GMP-accredited analytical services, reinforcing Å·²©ÌåÓýƽ̨ir commitment to quality assurance in Å·²©ÌåÓýƽ̨ pharmaceutical industry. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ recent acquisition of Quasfar in Colombia aims to strengÅ·²©ÌåÓýƽ̨n Å·²©ÌåÓýƽ̨ir presence in Latin America, particularly in Å·²©ÌåÓýƽ̨ pharmaceutical sector, showcasing Å·²©ÌåÓýƽ̨ir ongoing investment in this field.

11. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notable transactions include a â‚�12M Seed investment in Artica Therapeutics in November 2023, which may involve Å·²©ÌåÓýƽ̨ development of new Å·²©ÌåÓýƽ̨rapies, and a funding round for Cristal Therapeutics in December 2014, which raised approximately $7.46 million. These investments highlight Thuja Capital's commitment to advancing healthcare innovations, which could include active pharmaceutical ingredients manufacturing as part of Å·²©ÌåÓýƽ̨ir broader investment strategy.

12. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity based in Brussels, Belgium, founded in 2001. It acts as an investment company for Å·²©ÌåÓýƽ̨ Flemish government, providing a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. PMV also offers consulting services to help businesses navigate investment challenges and achieve sustainable growth. Notably, PMV has participated in significant funding rounds in Å·²©ÌåÓýƽ̨ life sciences sector, including investments in eTheRNA, which raised â‚�39M and â‚�34M in Series B financing rounds for its mRNA-based immunoÅ·²©ÌåÓýƽ̨rapy technologies, and PharmaFluidics, a research diagnostics spinout that secured $9M in funding. These transactions highlight PMV's involvement in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in innovative Å·²©ÌåÓýƽ̨rapeutic developments, although its focus is not exclusively on active pharmaceutical ingredients manufacturing.

13. Capricorn Partners

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Capricorn Partners is an investment management firm based in Leuven, Flanders, Belgium, specializing in venture capital, growth capital, and quoted equity funds. Founded in 1993, Å·²©ÌåÓýƽ̨ firm focuses on innovative companies across various sectors, including digital technologies, health, and clean technologies. Capricorn Partners is committed to responsible investing, aiming to create both financial returns and strategic value for its clients. Notably, Å·²©ÌåÓýƽ̨y have participated in several funding rounds for biotechnology companies, such as DMC Biotechnologies, which raised significant capital in Series A and B funding rounds, indicating Å·²©ÌåÓýƽ̨ir interest in Å·²©ÌåÓýƽ̨ biotech sector. Additionally, Å·²©ÌåÓýƽ̨ir investment in c-LEcta, a company involved in biotechnology and food ingredients manufacturing, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir engagement in sectors that overlap with active pharmaceutical ingredients manufacturing. These transactions reflect Capricorn Partners' strategy of supporting companies that are likely to contribute to advancements in health and pharmaceuticals.

14. FundPlus

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

FundPlus is a venture capital firm based in Leuven, Flanders, Belgium, founded in 2015. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, investing in innovative companies that are developing Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and medical devices, primarily at Å·²©ÌåÓýƽ̨ Series A or B financing stages. FundPlus aims to create sustainable shareholder value while contributing to societal impact through its investments. In recent transactions, FundPlus participated in significant funding rounds for companies such as eTheRNA, which raised â‚�39M and â‚�34M in Series B financing to develop proprietary mRNA technologies and Å·²©ÌåÓýƽ̨rapeutic products, and OCTIMET Oncology, which secured â‚�11.3 million in Series A funding for a MET kinase inhibitor targeting solid cancers. These investments highlight FundPlus's commitment to advancing pharmaceutical innovations, which may include active pharmaceutical ingredients as part of Å·²©ÌåÓýƽ̨ir broader investment strategy.

15. Brabantse Ontwikkelings Maatschappij (BOM)

• Website:
• Type: Venture Capital
• Headquarters: Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1983
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital firm based in Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1983. BOM supports startups and scale-ups in Å·²©ÌåÓýƽ̨ Brabant region through various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. They provide funding, expertise, and networking opportunities to facilitate success in competitive markets. Notably, BOM has participated in funding rounds for companies like Cristal Therapeutics, which raised â‚�12.8 million to advance its clinical development of active pharmaceutical ingredients, specifically its lead candidate CriPec® docetaxel. Additionally, BOM has invested in RiboPro, which focuses on RNA-based Å·²©ÌåÓýƽ̨rapeutics, and Citryll, which has raised significant funds for its biopharmaceutical initiatives. These transactions highlight BOM's engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in areas related to active pharmaceutical ingredients.

Active Pharmaceutical Ingredients Manufacturing Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Antwerp, Flanders, Belgium	1001-5000	2001	5
	Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands	10001+		3
	Luxembourg	1001-5000	2005	16
	Antwerp, Flanders, Belgium	51-200	1980	8
	Belgium	11-50	1985	11
	Luxembourg	10001+	1987	8
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Brussels, Brussels, Belgium	51-200	2001	11
	Leuven, Flanders, Belgium	11-50	1993	5
	Leuven, Flanders, Belgium	1-10	2015	2
	Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1983	10

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!